Drug Profile
Research programme: phosphodiesterase V inhibitors - Eisai
Latest Information Update: 17 Nov 2006
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 10 Nov 1997 Preclinical development for Thrombosis in Japan (Unknown route)